Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | GALK1 | P51570 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HK1 | P19367 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804593 | 1.00 | MAOA (0.38) | MAOAMAOBHSD17B3MEN1KMT2A | |
| SCHEMBL30483749 | 0.78 | MAOA (0.36) | MAOAMAOBCDC25B | |
| SCHEMBL29593696 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL4739721 | 0.74 | KDM4E (0.33) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL1758940 | 0.72 | IDO1 (0.33) | IDO1 | |
| SCHEMBL30997931 | 0.69 | MAPT (0.38) | MAOAMAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL536721 | 0.69 | MAPT (0.38) | MAOAMAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL27798673 | 0.69 | IDO1 (0.32) | IDO1 | |
| SCHEMBL1357123 | 0.68 | IDO1 (0.31) | IDO1 | |
| SCHEMBL7675144 | 0.68 | IDO1 (0.31) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-5801190-A | Fused pyrrolo 2,3-C! carbazole-6-ones | CEPHALON, INC. (US) | 1998-09-01 | — | — | US | claimed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2022-07-05 | — | — | US | disclosed |
| EP-3760607-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | Takasago International Corporation (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-12-24 | — | — | US | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-6821644-B2 | BIS(DIARYLAMINO)ARYLENE COMPOUND; BRILLIANCE, DURABILITY | SAMSUNG SDI CO., LTD. (KR) | 2004-11-23 | — | — | US | disclosed |
| CN-1098266-C | Fused pyrrolo (2,3-C) carbazole-6-ones which potentiate activity of gamma interferon | CEPHALON INC (US) | 2003-01-08 | — | — | CN | disclosed |
| CN-1098266-C | Fused pyrrolo (2,3-C) carbazole-6-ones which potentiate activity of gamma interferon | CEPHALON INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-0885229-B1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON INC (US) | 2000-08-02 | — | — | EP | disclosed |
| CN-1211254-A | Fused pyrrolo (2,3-C) carbazole-6-ones which potentiate activity of gamma interferon | CEPHALON INC (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1211254-A | Fused pyrrolo (2,3-C) carbazole-6-ones which potentiate activity of gamma interferon | CEPHALON INC (US) | 1999-03-17 | — | — | CN | disclosed |
| EP-0885229-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5801190-A | Fused pyrrolo 2,3-C! carbazole-6-ones | CEPHALON, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5801190-A | Fused pyrrolo 2,3-C! carbazole-6-ones | CEPHALON, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5801190-A | Fused pyrrolo 2,3-C! carbazole-6-ones | CEPHALON, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1997031002-A9 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997031002-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5616724-A | FOR POTENTIATION OF HUMAN INTERFERON-GAMMA; IMMUNOLOGY | CEPHALON, INC. (US) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | NEK4, TENT4A, TCF4 | MAOA 2320/4885MAOB 2240/4885HSD17B3 2623/4885 |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | NEK4, TENT4A, TCF4 | MAOA 2320/4885MAOB 2240/4885HSD17B3 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.